Gilead Sciences, Inc., is an American biotechnology company that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi. Wikipedia
CEO: Daniel O'Day (1 Mar 2019–
Headquarters: Foster City, California, United States
Revenue: 22.13 billion USD (2018)
Their current market cap is about US$92 billion.
I had a conference call some years ago with the Gilead Directors, the subject matter of which is not relevant here, but I was a long call with quite some detail and I was impressed by their diligence, indepth knowledge, sincerity and desire to contribute to humanity and increase their antiviral base. I smell some synergy between Gilead and MSB. I doubt it will be a take over offer, but Gilead would be a perfect finanical partner for MSB.
This is not investment advice, just an observation. Go MSB Go.
Gilead vs Mesoblast, page-4
-
- There are more pages in this discussion • 271 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.030(2.03%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.51 | $1.43 | $6.613M | 4.498M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2482 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 27045 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |